An observational study in Parkinsons Disease (PD), sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Washington University School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Parkinson Disease by Washington University School of Medicine — 7 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Washington University School of Medicine.
Among the 32 studies in Parkinson Disease by Washington University School of Medicine, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2025, is one of 13 observational ones, and was the 31st registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →7 of the 32 studies in Parkinson Disease by Washington University School of Medicine are open now, in 2 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 50+
Washington University School of Medicine · Sites in United States
Ages 50+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Washington University School of Medicine · Sites in United States
Ages 50+ · Healthy volunteers
Washington University School of Medicine · Sites in United States, Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1
First in 2004; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 120 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 31 across the 19 interventional studies, 174 across the 13 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
1 of the studies in Parkinson Disease by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05826457Washington University School of MedicineNorth American Prodromal Synucleinopathy Consortium Stage 2 | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Parkinson Disease by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's Disease (PD) is a neurodegenerative disorder caused by dysfunction in both subcortical structures and the cortex. The investigators recently discovered a new brain system called the Somato-Cognitive Action Network (SCAN), which could be a primary locus of dysfunction in PD. Here, the investigators will use magnetic resonance imaging techniques in PD patients to test whether SCAN is critical for PD. The investigators will determine whether SCAN is connected to PD-relevant subcortical structures, and whether PD patients exhibit altered subcortical-to-SCAN connectivity. If successful, this work will identify SCAN as a specific circuit altered in PD patients that can serve as a new target for future neuromodulatory PD therapies.
Parkinson's Disease (PD) is a neurodegenerative disease that causes symptoms such as tremor, bradykinesia, and freezing of gait, as well as sleep disturbance, autonomic dysfunction, and abulia. PD patients particularly struggle to initiate and maintain actions, which causes gait freezing, leading to falls. PD results from dysfunction in motor circuitry, including connections between subcortical structures such as substantia nigra and striatum, as well as primary motor cortex, which drives voluntary movement.
Recently, our group rewrote the textbook diagrams of motor circuitry. The investigators described a previously unrecognized Somato-Cognitive Action Network (SCAN) which is interspersed between effector-specific regions of primary motor cortex (foot, hand, mouth). The SCAN is engaged by coordinated rather than isolated actions, and it is strongly preferentially connected to other cortical regions important for action planning and control, autonomic function, and arousal.
Many SCAN functions (drive to act, gait, autonomic control, arousal, motor coordination) are affected in PD. Further, clinical targets for neuromodulation in PD are connected to SCAN. Thus, SCAN dysfunction might be an important aspect of PD pathophysiology and resulting symptoms. Critically, recent technical advances in noninvasive functional neuroimaging allow us for the first time to reliably evaluate the connectivity of motor systems, including SCAN, into the deep subcortical structures most relevant for PD.
Using these patient-oriented techniques, the investigators will first test whether PD-relevant subcortical structures-including clinical targets for PD-are connected more strongly to the SCAN circuit than to effector-specific M1 foot, hand, and mouth regions. The investigators will then test whether these subcortical-to-SCAN circuits are altered in PD patients to a greater degree than effector-specific circuits.
This work will advance a new conceptualization of PD as a disorder of SCAN rather than of traditional effector-specific M1, which will revolutionize how the investigators think of the disorder. Localizing PD disruption to specific portions of M1 could aid with evaluation of patients using these advanced, noninvasive fMRI techniques, and can provide precision targets of interest for other imaging modalities. Noninvasive mapping of cortico-subcortical connectivity will enable optimal target definition for neuromodulatory treatment of PD. Reconceptualizing PD as a disorder of SCAN, a system for integrated action, rather than of M1 circuits for isolated movement, may spur development of alternate symptom evaluation tools oriented around this framework. Finally, localizing M1 sites of disruption in PD opens the possibility of treating PD using cortical stimulation, a less-invasive alternative to deep brain stimulation.
Parkinson's Disease (PD) Patients
Age-matched Healthy Controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neurological Disorders (other than PD)
- Any other neurological condition
Significant Head Injury
Psychiatric Disorders
Serious Medical Conditions
Cognitive Impairment
MRI
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* 70 non-demented individuals with clinically definite PD * Must be 40 years of age or older * Both male \& female
* 50 individuals with normal neurological exams and cognition * No first-degree relatives with PD * Also, must be 40 years of age or older
Cortico-subcortical connectivity to SCAN vs effectors
We will collect resting-state functional magnetic resonance imaging (fMRI) scans from the brains of all participants. From the fMRI scans, we will compute the functional connectivity between each of the subcortical brain structures relevant for Parkinson's disease (including substantia nigra, subthalamic nucleus, globus pallidus internus, and ventral intermediate nucleus of the thalamus) and each subdivision of primary motor cortex (Somato-Cognitive Action network and effector-specific regions controlling the hand, foot, and face). Functional connectivity will be computed as pairwise temporal correlations of the activity timecourses in each location. We hypothesize that subcortical structures will exhibit differential functional connectivity to the Somato-Cognitive Action network than to the effector-specific regions of primary motor cortex.
Time frame: 6 months per participant; 3-4 sessions for controls, 6-8 sessions for PD patients
Cortico-subcortical connectivity to SCAN in Parkinson's and controls
We will collect resting-state functional magnetic resonance imaging (fMRI) scans from the brains of all participants. From the fMRI scans, we will compute the functional connectivity between each of the subcortical brain structures relevant for Parkinson's disease (including substantia nigra, subthalamic nucleus, globus pallidus internus, and ventral intermediate nucleus of the thalamus) and each subdivision of primary motor cortex (Somato-Cognitive Action network and effector-specific regions controlling the hand, foot, and face). Functional connectivity will be computed as pairwise temporal correlations of the activity timecourses in each location. We hypothesize that people with Parkinson's Disease will exhibit differential functional connectivity than controls between subcortical structures and the Somato-Cognitive Action network.
Time frame: 6 months per participant; 3-4 sessions for controls, 6-8 sessions for PD patients
Plan to share: Yes — IPD, including de-identified neuroimaging data, summary measures from clinical and motor assessments, summary measures from behavioral tasks, summary measures from psychiatric questionnaires, \& anonymized demographic data.
Supporting information: Analytic code
Time frame: IPD and supporting information will be available after initial publication and shared indefinitely.
Access criteria: IPD and supporting information will be publicly accessible through the OpenNeuro repository (https://openneuro.org). Openneuro provides a persistent unique Accession Number for deposited datasets. All publications associated with this data will reference that Accession Number.
Started Aug 2025 (actual). Primary completion is estimated for Jan 2031, 65 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 65 months is above that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →